Menu
Not yet recruiting NCT06055764

Role of FDG PET/CT in Patients With Metastasis of Unknown Origin

— Observational Metastasis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: PET/CT.
Who it may be relevant to
Registry conditions: Metastasis. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

Evaluatation of the role of F18FDG-PET/CT in patients with metastases of unknown origin.

Detailed description

Cancer of unknown primary origin (CUP) includes a cluster of heterogeneous tumors that have exceptional clinical features: it is defined as early apparent metastatic disease with no recognizable primary site at the time of presentation. The incidence of CUP ranges around 2% of all new cancer diagnoses.

The work up list of CUP include; a biopsy proven malignancy, a detailed physical examination, many laboratory, radiological and endoscopy. However, these investigations may be costly time-consuming and may eventually fail to detect the site of the primary malignant tumor in the majority of patients. In this context, positron-emission tomography (PET) combined with computed tomography (PET/CT), using the radiotracer 18F fluoro- 2-deoxyglucose (FDG) is an alternative, non-invasive imaging modality with accurate diagnostic performance. It considered good tool for diagnosis of patients with CUP . The basis for use of FDG as radiotracer for PET imaging in CUP depends on the fact that most of the malignant cancer phenotypes show an increased glucose metabolism rate.

Failure to identify the primary tumor hampers optimization of management planning, which in turn may adversely influence patient prognosis.

Interventions

  • Device PET/CT
    Patient preparation: Patients will fast for 4 - 6 h before PET scanning to optimize the blood sugar level to 160mg/dl. F-18 FDG dose was 0.14 mCi/kg and injected via intravenous route. During the uptake phase of 18F-FDG patients will be rested in a quite warm room. Procedure: All PET-CT studies will be done at the nuclear medicine unit in Assuit University Hospital. PET-CT images will be interpreted at a workstation equipped with fusion software that offers multi-planar reformatted images and

Primary outcome measures

  • Role of FDG PET/CT in patients with metastasis of unknown origin. Role of FDG PET/CT in patients with metastasis of unknown origin. [Time frame: through study completion an average 2 years]

Eligibility criteria

Inclusion criteria

  • Patients with age more than 18 years presented with either pathologically proved metastases of unknown primary or
  • Patients with clinico-radiological suspicious of having metastases.

Exclusion criteria

  • • Age below 18 years,
  • patients with pathologically proved primary tumor,
  • Patients suffering from advanced disease and in-cooperative patients.
  • Pregnant and lactating women.
  • Patients who had motion artifacts, or those who can't stay stable or calm during acquisition.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Other

Study locations

Center list to be confirmed — check the primary protocol.

Publications

  • Park JS, Yim JJ, Kang WJ, Chung JK, Yoo CG, Kim YW, Han SK, Shim YS, Lee SM. Detection of primary sites in unknown primary tumors using FDG-PET or FDG-PET/CT. BMC Res Notes. 2011 Mar 9;4:56. doi: 10.1186/1756-0500-4-56. PMID 21385465
  • Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol. 2009 Mar;19(3):731-44. doi: 10.1007/s00330-008-1194-4. Epub 2008 Oct 17. PMID 18925401

Identifiers

NCT: NCT06055764 · PET/CT in MUO

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗